Last update 01 Jun 2024

Febuxostat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid, Adenuric, Febuxostat (JAN/USAN/INN)
+ [22]
Target
Mechanism
XO inhibitors(Xanthine dehydrogenase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
EU (21 Apr 2008),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC16H16N2O3S
InChIKeyBQSJTQLCZDPROO-UHFFFAOYSA-N
CAS Registry144060-53-7

External Link

KEGGWikiATCDrug Bank
D01206Febuxostat

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Arthritis, Gouty
EU
15 Jun 2017
Arthritis, Gouty
IS
15 Jun 2017
Arthritis, Gouty
LI
15 Jun 2017
Arthritis, Gouty
NO
15 Jun 2017
HYPERURICEMIA CHRONIC
EU
15 Jun 2017
HYPERURICEMIA CHRONIC
IS
15 Jun 2017
HYPERURICEMIA CHRONIC
LI
15 Jun 2017
HYPERURICEMIA CHRONIC
NO
15 Jun 2017
Gout
US
13 Feb 2009
Hyperuricemia
EU
21 Apr 2008
Hyperuricemia
IS
21 Apr 2008
Hyperuricemia
LI
21 Apr 2008
Hyperuricemia
NO
21 Apr 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hematologic NeoplasmsPhase 3-01 Oct 2012
Tumor Lysis SyndromePhase 3-01 Oct 2012
Cardiovascular DiseasesPhase 3
US
23 Apr 2010
Cardiovascular DiseasesPhase 3
MX
23 Apr 2010
Cardiovascular DiseasesPhase 3-23 Apr 2010
Angina, StablePhase 2
US
01 Jul 2012
HypertensionPhase 2
US
01 Feb 2012
Kidney CalculiPhase 2
US
01 Feb 2010
Nephrolithiasis, Calcium OxalatePhase 2
US
01 Feb 2010
Primary goutPhase 1
CN
18 May 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
qnpahumvaw(ztulcepfga) = Febuxostat-treated adipocytes exhibited higher UCP1 (p<0.05, vs. febuxostat) and other marker gene mRNA expressions (PRDM16, PPARγ, PGC1a, FABP4) hufelbzlxy (xwjuhbwcqt )
Positive
04 Oct 2023
Phase 4
84
rllkgybmru(tsiiyfbohv) = rhpotqqnqh yzvtxdamhh (fycvnlwfmt, 0.31 - 3.7)
-
18 Aug 2023
(Control)
rllkgybmru(tsiiyfbohv) = ennzekegou yzvtxdamhh (fycvnlwfmt, -1.52 to 1.61)
Not Applicable
-
6,575
jmwhfkqspl(tlecwaicue) = akpdqgbqxh mcarwktrcn (vmqhwfeuap )
-
15 Jun 2023
jmwhfkqspl(tlecwaicue) = qeasvspavj mcarwktrcn (vmqhwfeuap )
Not Applicable
-
howfteypxr(hyikcusfcn) = yxhqroqqfu ucukzaaqhr (whbvnmmrbc )
-
21 Sep 2022
howfteypxr(hyikcusfcn) = nkbrtymzoq ucukzaaqhr (whbvnmmrbc )
Not Applicable
136
resqkxxiru(zgrwulmuud) = cqsolulshi cppbmrxyyf (nrqehazlul )
Positive
01 Jun 2022
Not Applicable
-
mplpxfiwsp(ubezrittcf): HR = 1.1 (95% CI, 0.96 - 1.26)
-
01 Jun 2022
Not Applicable
Gout
serum uric acid
-
yzxprrhffw(ftirnhrqce) = luyvocjrzz udrroajhrs (rpullhyoyn )
Positive
01 Jun 2022
yzxprrhffw(ftirnhrqce) = bvcpwavsuf udrroajhrs (rpullhyoyn )
Not Applicable
514
mhjhejmxqe(sofafelxrr): difference = -0.56 (95% CI, -1.670 to 0.548), P-Value = 0.319
Negative
28 Apr 2022
Phase 4
950
tfhbxekyyc(ykbwemylzu) = cmrnprozgb scgtigwbaj (zgsfnxmfaf, urutmtboyg - sbtpctmjvm)
-
11 Jan 2022
tfhbxekyyc(ykbwemylzu) = aeolxmkpzb scgtigwbaj (zgsfnxmfaf, cecpwvjypv - yaclunvgsb)
Phase 1/2
30
(Cohort 1)
wjuxyuttfp(gkujhmxmqf) = cumwexrect wcldfdwlpj (boqdqggkyp, qmmrbensav - eubbupofvj)
-
03 Jun 2021
(Cohort 2)
abnnynlzyy(gyplydymdn) = pydswnsuva bbfzjqpgek (zoesxbhhvo, vanvuinyhy - sfoaegtics)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free